A career in biotechnology can be read as a list of molecules, job titles and trial numbers. Jieyi Wang’s makes more sense as a sequence of constraints. First came the discipline of pharmacology: a drug must do more than bind; it must produce a controlled effect. Then came two decades inside large-company oncology research, where a promising idea has to survive engineering, manufacturing and clinical translation. Finally came the founder’s version of the same problem. If immune activation is powerful but context matters, can the molecule itself be designed to wait for the right context?
Wang founded Lyvgen Biopharma in 2016 after 22 years at Abbott and AbbVie. By then he had already worked across several generations of antibody design. His published record includes conventional monoclonal antibodies, dual-variable-domain immunoglobulins, a MET-targeted antibody-drug conjugate and conditional T-cell engagement. Lyvgen was not a departure from that work. It was an attempt to organize a company around one of its persistent questions.
In public, Wang describes his remit with unusual compression. His LinkedIn summary reads: “R & D of innovative biotherapeutics.” The company description adds the mechanism. Lyvgen’s xLinkAb platform is built to generate agonist antibodies whose activity depends on cross-linking, including engagement of FcγRIIB. The ambition is to treat location and receptor context as part of the drug’s logic.
The apprenticeship before the company
Wang’s technical education began at Shanghai Medical University, now part of Fudan University, where he earned bachelor’s and master’s degrees. He then moved to the State University of New York at Stony Brook for a Ph.D. in molecular and cellular pharmacology, completed in 1994. The sequence matters. Pharmacology asks not only whether a molecule touches a target, but what follows from that contact, at what dose and under which conditions.
He joined Abbott and remained through the creation of AbbVie, eventually holding senior research roles in oncology. Company biographies credit him with leading teams that moved multiple antibody protein drugs into clinical development. One program became telisotuzumab vedotin, previously ABBV-399, an antibody-drug conjugate directed at the MET receptor. A 2017 paper with Wang as first author described how the conjugate could target both MET-amplified and MET-overexpressing tumors. Another paper examined ABT-700, an anti-MET monoclonal antibody, and how it disrupted signaling in tumors with MET amplification.
These projects sit on different branches of the antibody family tree, but they share an engineering attitude. Binding is only the opening move. An antibody can block a receptor, carry a payload, bring two targets together or stimulate a signal. Each added function creates another dependency. The more a molecule is asked to do, the more carefully its conditions have to be specified.
“Innovation originates from science and depends on science; clinical development has no existing path.”Jieyi Wang, following Lyvgen’s Series C financing · translated from Chinese
Wang’s later AbbVie work included multifunctional formats. In a paper on Half DVD-Ig molecules, researchers described antibodies designed to redirect T cells conditionally. The conceptual thread is visible: control does not have to come only from how much drug is given. It can also be built into the interactions the molecule requires before it acts.
A molecule with an if-statement
Agonist antibodies present a special design problem. Instead of blocking a receptor, they activate one. Many immune receptors signal most effectively when several copies are clustered. An antibody can provide part of that geometry, but the strength and location of the effect depend on how its arms and Fc region interact with receptors around it.
Lyvgen’s xLinkAb approach makes that second interaction central. Its lead programs include exlinkibart, also called LVGN6051, which targets CD137 or 4-1BB, and LVGN7409, which targets CD40. Both receptors belong to a family involved in immune-cell signaling. The candidates are designed so that FcγRIIB-mediated cross-linking helps organize the agonist effect. In plain English: the antibody is not treated as a lone key. It is designed as a piece of a local assembly.
That is the founder’s thesis expressed as molecular architecture. It is also the organizing thesis of the business. A platform is useful only if it produces candidates; candidates are useful only if they can be made consistently; clinical programs matter only if their designs can test the intended mechanism. Lyvgen’s footprint reflects those handoffs, with research in Shanghai, process development and manufacturing capability in Suzhou, and clinical and business-development work spanning China and the United States.
That geography also mirrors Wang’s own path. His scientific training began in Shanghai, continued in New York, and led to industry work in North Chicago and Redwood City. Lyvgen’s map reverses and recombines that route. Discovery work can sit near the company’s Shanghai base. Process development and manufacturing capability can be built in Suzhou. Clinical studies, regulatory work and partnerships can move through teams on both sides of the Pacific. None of those locations proves that the model works. Together, they show what the model demands: a founder who can translate the same technical premise among scientists, operators, physicians, manufacturers and partners.
Translation is often treated as communication polish. In drug development it is closer to systems engineering. A discovery team has to describe an antibody in terms a process team can reproduce. The process team has to create material that can enter a regulated study. Clinical collaborators have to turn the intended mechanism into eligibility rules, dose schedules and measurable outcomes. A platform founder therefore spends much of the job moving an idea between professional languages without letting its important conditions disappear. Wang’s career supplied repeated practice at precisely those handoffs.
Turning a platform diagram into a trial
The company began a Phase 1 study of LVGN6051 in 2019, evaluating it alone and in combinations. In 2020, Lyvgen announced a collaboration with MSD to study the candidate alongside pembrolizumab. LVGN7409 entered first-in-human dosing in early 2021. That same year, Lyvgen completed a Series C financing led by IDG Capital and presented an LVGN6051 trial-in-progress update at the American Society of Clinical Oncology annual meeting.
The sequence is less tidy than a pitch deck. Platform development, manufacturing, partnerships and trials overlap. Lyvgen opened a 2,000-square-meter therapeutic-antibody CMC center in Suzhou in 2020, while clinical work was already moving. In 2022, the company published a review explaining the role of FcγRIIB cross-linking in activating members of the TNF receptor superfamily. The scientific explanation followed the operational work in parallel.
Wang completes his Stony Brook Ph.D. and begins the long Abbott and AbbVie chapter.
Lyvgen is founded, turning accumulated antibody experience into a platform company.
The company announces an MSD trial collaboration and opens antibody process-development capacity in Suzhou.
Two exlinkibart studies are selected for ASCO, including work in resistant solid tumors and soft tissue sarcoma.
Wang appears on the BIOCHINA program to discuss a B7H3×CD3×PD-L1 trispecific T-cell engager; a U.S. anti-CD40 patent naming him is granted.
By the 2024 ASCO meeting, two exlinkibart clinical studies had been selected for presentation. One covered combinations in resistant non-small-cell lung cancer, melanoma and gastrointestinal malignancies. Another, co-authored by Wang, reported on a Phase 1b/2 study with anlotinib in refractory soft tissue sarcoma. Lyvgen also announced approval in China to begin a Phase 2 study of an LVGN6051 combination in head and neck squamous cell carcinoma.
Those milestones do not settle the scientific question, and Wang’s own language resists pretending they do. In remarks around the Series C round, he said clinical development must be explored and validated against clinical need, and that the process requires preparation and patience. It is a revealing founder statement because it treats uncertainty as the work, not as a temporary inconvenience before certainty arrives.
The patience encoded in the design
There are flashier ways to narrate a biotech founder. Wang’s public record favors continuity. He trained in pharmacology, spent decades with antibody programs, published what those molecules taught, then built new formats around the limitations he kept encountering. Even his recent work stays inside the same frame. A 2026 conference agenda listed him speaking about a trispecific T-cell engager targeting B7H3, CD3 and PD-L1. A U.S. patent granted that June named him and Yi Wu as inventors on anti-CD40 binding molecules and bispecific antibodies.
The formats grow more elaborate, but the principle remains legible: an antibody can integrate information. One interaction identifies a target. Another establishes context. Together they determine whether a signal should proceed. This is molecular engineering as conditional logic, learned through a career of watching what happens after binding.
“I founded Lyvgen with the intention of leveraging my years of experience in innovative drug research and development.”Jieyi Wang
Experience alone is not a strategy. Its value lies in compression: recognizing which variables matter, which risks can be designed around and which uncertainties must be tested in people. Wang’s 22 years before Lyvgen gave him a large archive of those judgments. The company is the attempt to make them systematic.
That may be the useful part of his story for anyone building technical work over a long horizon. The second act did not discard the first. It concentrated it. Lyvgen’s molecules need a second signal; Wang’s company needed the first 22 years.